Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,948 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) versus Viread for the treatment of chronic hepatitis B: First-stage results at week 48.
Liang RY, Xu JH, Si CW, Wang S, Shang J, Yu ZJ, Mao Q, Xie Q, Zhao W, Li J, Gao ZL, Wu SM, Tang H, Cheng J, Chen XY, Zhang WH, Wang H, Xu ZN, Wang L, Dai J, Yu YY. Liang RY, et al. Among authors: shang j. Medicine (Baltimore). 2019 Aug;98(33):e16778. doi: 10.1097/MD.0000000000016778. Medicine (Baltimore). 2019. PMID: 31415381 Free PMC article. Clinical Trial.
Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings.
Xu DZ, Wang XY, Shen XL, Gong GZ, Ren H, Guo LM, Sun AM, Xu M, Li LJ, Guo XH, Zhen Z, Wang HF, Gong HY, Xu C, Jiang N, Pan C, Gong ZJ, Zhang JM, Shang J, Xu J, Xie Q, Wu TF, Huang WX, Li YG, Xu J, Yuan ZH, Wang B, Zhao K, Wen YM; YIC Efficacy Trial Study Team. Xu DZ, et al. Among authors: shang j. J Hepatol. 2013 Sep;59(3):450-6. doi: 10.1016/j.jhep.2013.05.003. Epub 2013 May 11. J Hepatol. 2013. PMID: 23669281 Clinical Trial.
Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection.
Rao H, Wei L, Lopez-Talavera JC, Shang J, Chen H, Li J, Xie Q, Gao Z, Wang L, Wei J, Jiang J, Sun Y, Yang R, Li H, Zhang H, Gong Z, Zhang L, Zhao L, Dou X, Niu J, You H, Chen Z, Ning Q, Gong G, Wu S, Ji W, Mao Q, Tang H, Li S, Wei S, Sun J, Jiang J, Lu L, Jia J, Zhuang H. Rao H, et al. Among authors: shang j. J Gastroenterol Hepatol. 2014 Mar;29(3):545-53. doi: 10.1111/jgh.12398. J Gastroenterol Hepatol. 2014. PMID: 24090188 Free PMC article.
Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon.
Hou FQ, Song LW, Yuan Q, Fang LL, Ge SX, Zhang J, Sheng JF, Xie DY, Shang J, Wu SH, Sun YT, Wei SF, Wang MR, Wan MB, Jia JD, Luo GH, Tang H, Li SC, Niu JQ, Zhou WD, Sun L, Xia NS, Wang GQ. Hou FQ, et al. Among authors: shang j. Theranostics. 2015 Jan 1;5(3):218-26. doi: 10.7150/thno.10636. eCollection 2015. Theranostics. 2015. PMID: 25553110 Free PMC article. Clinical Trial.
[High sustained virological response to optimized therapy for refractory chronic hepatitis C treatment-na(i)ve patients: a multicenter randomized study].
Chen X, Shang J, Yang R, Xie Q, Gao Z, Xu X, Dou X, Gong G, Chen G, Li J, Chen H, Zhang D, Feng Y, Niu J, Hou J, You H, Wu Y, Zhao P, Rao H, Wei L. Chen X, et al. Among authors: shang j. Zhonghua Gan Zang Bing Za Zhi. 2015 Jun;23(6):412-7. doi: 10.3760/cma.j.issn.1007-3418.2015.06.004. Zhonghua Gan Zang Bing Za Zhi. 2015. PMID: 26236925 Clinical Trial. Chinese.
2,948 results